AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22281165 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% cream
Number of subjects: 0
Study 22281165 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream
Number of subjects: 0
Study 20175820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromotetrandrine (BrTet) 10 mg/m²
Number of subjects: 30
Study 20175820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromotetrandrine (BrTet) 20 mg/m²
Number of subjects: 30
Study 20175820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromotetrandrine (BrTet) 30 mg/m²
Number of subjects: 30
Study 17099077 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg ipratropium bromide
Number of subjects: 14
Study 17099077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16164589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trial (RCT)
Number of subjects: 0
Study 12039122 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism (T allele)
Number of subjects: 207
Study 12039122 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR genotype frequencies
Number of subjects: 207
Study 12039122 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum homocysteine levels
Number of subjects: 207
Study 11088064 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endocrine therapy (3 to 4 months duration)
Number of subjects: 0
Study 11088064 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 8803300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril with or without diuretics
Number of subjects: 76
Study 8803300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine with or without diuretics
Number of subjects: 76
Study 8803300 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (diuretics with or without vasodilators or selective beta-blockers)
Number of subjects: 76
Study 1385827 — intervention group
Group type: EXPERIMENTAL
Intervention: High sun exposure and low CD4/CD8 ratio
Number of subjects: 61
Study 1385827 — intervention group
Group type: COMPARATOR
Intervention: Low sun exposure and high CD4/CD8 ratio
Number of subjects: 61
Study 1385827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior basal cell carcinoma and sun exposure
Number of subjects: 61
Study 1385827 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 61
Study 1385827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4/CD8 ratio
Number of subjects: 61
Study 6364896 — intervention group
Group type: EXPERIMENTAL
Intervention: Human IgE pentapeptide (HEPP)
Number of subjects: 12
Study 6364896 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 12
Study 29807945 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing contrast (0.3 mL)
Number of subjects: 41
Study 29807945 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 41
Study 29183947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=370) reduced worktime to 75% with preserved salary during 18 months
Number of subjects: 636
Study 28607880 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conchal cartilage
Number of subjects: 100
Study 28607880 — intervention group
Group type: COMPARATOR
Intervention: Homologous septal cartilage
Number of subjects: 100
Study 26655888 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir-fermented milk (1,600 mg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg)
Number of subjects: 40
Study 26655888 — intervention group
Group type: COMPARATOR
Intervention: Calcium bicarbonate (CaCO3, 1,500 mg) alone (control)
Number of subjects: 40
Study 23605599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser treatment
Number of subjects: 24
Study 22216772 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice recognition (IVR) intervention designed to prompt medication refills and improve ICS adherence
Number of subjects: 8517
Study 22216772 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8517
Study 22216772 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice recognition (IVR) intervention with 2 or more direct contacts or detailed messages
Number of subjects: 8517
Study 18482632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-pack therapy (vasoconstriction)
Number of subjects: 50
Study 18482632 — intervention group
Group type: COMPARATOR
Intervention: Sandbag application (compression-control)
Number of subjects: 50
Study 17135646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (2.3 mg/m2/d, days 1 through 5, every 21 days) plus best supportive care (BSC)
Number of subjects: 141
Study 17135646 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 141
Study 17135646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan
Number of subjects: 141
Study 12709112 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent pad changing regime
Number of subjects: 81
Study 12709112 — intervention group
Group type: COMPARATOR
Intervention: Less frequent pad changing regime
Number of subjects: 81
Study 11132072 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 20 mg/kg i.v.
Number of subjects: 160
Study 11132072 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide 0.25 mg/kg i.m.
Number of subjects: 160
Study 11132072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg i.v.
Number of subjects: 160
Study 11132072 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 1 mg/kg i.v.
Number of subjects: 160
Study 9252957 — intervention group
Group type: COMPARATOR
Intervention: Fish diet group (eating fish meals five times per week)
Number of subjects: 59
Study 9252957 — intervention group
Group type: COMPARATOR
Intervention: DHA oil group (1.68 g/d DHA in triglyceride form)
Number of subjects: 59
Study 9252957 — intervention group
Group type: COMPARATOR
Intervention: Fish oil group (1.33 g EPA and 0.95 g DHA/d as free fatty acids)
Number of subjects: 59
Study 9252957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 8162238 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809
Study 8162238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 3526532 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (62 mg/kg/day)
Number of subjects: 20
Study 3526532 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin (80 mg/kg/day)
Number of subjects: 20
Study 30340388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 12000
Study 30340388 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 12000
Study 30340388 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating system (HSR)
Number of subjects: 12000
Study 30340388 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning symbol
Number of subjects: 12000
Study 30340388 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 12000
Study 27253658 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (40, 80, and 150 mg)
Number of subjects: 36
Study 27253658 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (all doses)
Number of subjects: 36
Study 27253658 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 36
Study 27253658 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (15 and 30 mg)
Number of subjects: 36
Study 27253658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24385309 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg
Number of subjects: 40
Study 24385309 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg
Number of subjects: 40
Study 24385309 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 800 mg
Number of subjects: 40
Study 24385309 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (all doses)
Number of subjects: 40
Study 23623623 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT)
Number of subjects: 93
Study 23623623 — intervention group
Group type: COMPARATOR
Intervention: Standard Home Visiting (SHV)
Number of subjects: 93
Study 21052041 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER (75 to 225 mg/d)
Number of subjects: 520
Study 21052041 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine ER + Dialogues program
Number of subjects: 520
Study 18376124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 678
Study 18376124 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 678
Study 18376124 — intervention group
Group type: EXPERIMENTAL
Intervention: DI (Differential Index)
Number of subjects: 678
Study 18376124 — intervention group
Group type: EXPERIMENTAL
Intervention: SDNN (Standard Deviation of Normal-to-Normal intervals)
Number of subjects: 678
Study 18376124 — intervention group
Group type: EXPERIMENTAL
Intervention: PNN50 (Percent of differences between adjacent normal RR intervals >50 ms)
Number of subjects: 678
Study 18376124 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSSD (Root Mean Square of Successive Differences)
Number of subjects: 678
Study 18376124 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HRV measurements
Number of subjects: 678
Study 16632013 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan, 80 mg/d (titrated up to 160 mg/d for blood pressure control)
Number of subjects: 109
Study 16632013 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 109
Study 16632013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 12954916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-reducing drugs
Number of subjects: 12
Study 12954916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10963823 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.025 U/kg BW)
Number of subjects: 0
Study 10963823 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.05 U/kg BW)
Number of subjects: 0
Study 10963823 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (0.025 U/kg BW)
Number of subjects: 0
Study 10963823 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (0.05 U/kg BW)
Number of subjects: 0
Study 10963823 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (any dose)
Number of subjects: 0
Study 8626983 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite inhalation
Number of subjects: 20
Study 8626983 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20
Study 8139394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (30 g/d)
Number of subjects: 20
Study 8139394 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 20
Study 3413202 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 0
Study 3413202 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 29368598 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance exercise program (RT)
Number of subjects: 0
Study 29368598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AT)
Number of subjects: 0
Study 29368598 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment/control (CN)
Number of subjects: 0
Study 28118486 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Number of subjects: 42
Study 28118486 — intervention group
Group type: COMPARATOR
Intervention: Healthy Behaviors (Control)
Number of subjects: 42
Study 27310241 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching provided by trained lay coaches
Number of subjects: 223
Study 27310241 — intervention group
Group type: COMPARATOR
Intervention: Baseline psychological treatment
Number of subjects: 223
Study 27310241 — intervention group
Group type: COMPARATOR
Intervention: Baseline antidepressant medications
Number of subjects: 223
Study 23733443 — intervention group
Group type: EXPERIMENTAL
Intervention: HiDHA (tuna oil) supplementation (8 × 1 g capsules per day for 16 weeks)
Number of subjects: 95
Study 23733443 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo) supplementation (8 × 1 g capsules per day for 16 weeks)
Number of subjects: 95
Study 23733443 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis in the fish oil group
Number of subjects: 95
Study 21414950 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-triggered self-medication with chlordiazepoxide
Number of subjects: 165
Study 21414950 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule regimen with chlordiazepoxide
Number of subjects: 165
Study 19108693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5 vaccine
Number of subjects: 252
Study 19108693 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 vaccine
Number of subjects: 252
Study 19108693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 17884364 — intervention group
Group type: EXPERIMENTAL
Intervention: DANAMI score
Number of subjects: 1115
Study 17884364 — intervention group
Group type: COMPARATOR
Intervention: Veterans Affairs Medical Center score
Number of subjects: 1115
Study 17884364 — intervention group
Group type: COMPARATOR
Intervention: Duke treadmill score
Number of subjects: 1115
Study 17884364 — intervention group
Group type: COMPARATOR
Intervention: GISSI-2 score
Number of subjects: 1115
Study 15364161 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose of insulin glargine
Number of subjects: 292
Study 15364161 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dose of insulin glargine
Number of subjects: 292
Study 15364161 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose of insulin glargine
Number of subjects: 292
Study 15364161 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 292
Study 15364161 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (morning, evening, split)
Number of subjects: 292
Study 11998881 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (20 Gy in 10 fractions)
Number of subjects: 27
Study 11998881 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients, 4 well-defined, 11 occult)
Number of subjects: 27
Study 9894621 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (37.5 mg/day)
Number of subjects: 34
Study 9894621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8672317 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pressure applied on the neurovascular sheath during injection of 2% mepivacaine with adrenaline (20 ml) mixed with contrast agent (20 ml).
Number of subjects: 98
Study 8672317 — intervention group
Group type: COMPARATOR
Intervention: Digital pressure applied 6-8 cm below the neurovascular sheath during injection of 2% mepivacaine with adrenaline (20 ml) mixed with contrast agent (20 ml).
Number of subjects: 98
Study 2088996 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐mg controlled‐release morphine tablet (MS Contin Tablet) after a high fat meal
Number of subjects: 24
Study 2088996 — intervention group
Group type: COMPARATOR
Intervention: 30‐mg controlled‐release morphine tablet (MS Contin Tablet) after fasting
Number of subjects: 24
Study 391321 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 391321 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study 31221211 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based implementation approach
Number of subjects: 0
Study 31221211 — intervention group
Group type: COMPARATOR
Intervention: Non-theory based implementation approach
Number of subjects: 0
Study 28738490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration therapy for 8 hours
Number of subjects: 132
Study 28738490 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 132
Study 25099637 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive retroperitoneal approach (RPA)
Number of subjects: 60
Study 25099637 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach (TPA)
Number of subjects: 60
Study 23665375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 14
Study 23665375 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC) participants
Number of subjects: 14
Study 21233258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy at the third thoracic ganglion (G3)
Number of subjects: 40
Study 21233258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy at the fourth thoracic ganglion (G4)
Number of subjects: 40
Study 18423715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive spaced education on prostate cancer/prostate specific antigen
Number of subjects: 237
Study 18423715 — intervention group
Group type: COMPARATOR
Intervention: Web based teaching on benign prostatic hyperplasia/erectile dysfunction
Number of subjects: 237
Study 18423715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive spaced education on benign prostatic hyperplasia/erectile dysfunction
Number of subjects: 237
Study 18423715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive spaced education
Number of subjects: 237
Study 18423715 — intervention group
Group type: COMPARATOR
Intervention: Web based teaching
Number of subjects: 237
Study 16551138 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 120
Study 16551138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 14618096 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 0.5 x 10(5) KIU/Kg (Group B)
Number of subjects: 32
Study 14618096 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 1.0 x 10(5) KIU/Kg (Group C)
Number of subjects: 32
Study 14618096 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 32
Study 10891980 — intervention group
Group type: EXPERIMENTAL
Intervention: Microelectrode‐guided bilateral STN high‐frequency stimulation
Number of subjects: 15
Study 1932608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of enalapril (10 mg) and hydrochlorothiazide (25 mg)
Number of subjects: 12
Study 1932608 — intervention group
Group type: COMPARATOR
Intervention: Enalapril tablet (10 mg)
Number of subjects: 12
Study 1932608 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide tablet (25 mg)
Number of subjects: 12
Study 1932608 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous administration of separate tablets of enalapril (10 mg) and hydrochlorothiazide (25 mg)
Number of subjects: 12
Study 7015537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol HCl 160 mg slow-release plus cyclopenthiazide 0.25 mg and potassium chloride 600 mg
Number of subjects: 89
Study 7015537 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar regimen (not specified)
Number of subjects: 89
Study 31865273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 530
Study 30025819 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-peptide vaccines
Number of subjects: 0
Study 30025819 — intervention group
Group type: COMPARATOR
Intervention: Control patients (HLA-A2 negative)
Number of subjects: 0
Study 27514617 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg prasugrel
Number of subjects: 40
Study 27514617 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel
Number of subjects: 40
Study 24522636 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 824
Study 24522636 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Medical Research Council (mMRC) scale
Number of subjects: 824
Study 24522636 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in mMRC scale scores
Number of subjects: 824
Study 24522636 — intervention group
Group type: COMPARATOR
Intervention: COPD Assessment Test (CAT) in smokers without COPD
Number of subjects: 824
Study 21255943 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost arm (45 Gy in 25 fractions to the whole breast followed by a 16 Gy in 8 fraction electron boost)
Number of subjects: 688
Study 21255943 — intervention group
Group type: COMPARATOR
Intervention: No-boost arm (50 Gy in 25 fractions)
Number of subjects: 688
Study 18793808 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 166
Study 18793808 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 166
Study 18034674 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative dental materials in clinical trials
Number of subjects: 0
Study 18034674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials
Number of subjects: 0
Study 18034674 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory test values
Number of subjects: 0
Study 18034674 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment
Number of subjects: 0
Study 18034674 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based dentistry
Number of subjects: 0
Study 16144987 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) administered at bedtime
Number of subjects: 200
Study 16144987 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg/d) administered on awakening
Number of subjects: 200
Study 12117040 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (4.5, 18, and 54 microg via Turbuhaler)
Number of subjects: 28
Study 12117040 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 and 1800 microg via pMDI)
Number of subjects: 28
Study 12117040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10427133 — intervention group
Group type: EXPERIMENTAL
Intervention: ex vivo expanded hematopoietic cells and progenitors
Number of subjects: 6
Study 7489584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aktiferrin capsules
Number of subjects: 40
Study 7489584 — intervention group
Group type: COMPARATOR
Intervention: Tardyferon dragées
Number of subjects: 40